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Aims. To evaluate the association of different apelin levels with cardiovascular mortality, hospitalization, renal function, and
cardiovascular risk factors in type 2 diabetic patients with mild to moderate CKD. Methods. An observational, prospective study
involving 150 patients divided into groups according to baseline apelin levels: 1 ≤ 98 pg/mL, 2 = 98–328 pg/mL, and 3 ≥ 329 pg/mL.
Baseline characteristics were analyzed and compared. Multivariate Cox regression was used to find out predictors of cardiovascular
mortality, and multivariate logistic regression was used to find out predictors of hospitalization and disease progression. Simple
linear regressions andPearson correlationswere used to investigate correlations between apelin and renal disease and cardiovascular
risk factors. Results. Patients’ survival at 83 months in groups 1, 2, and 3 was 39%, 40%, and 71.2%, respectively (𝑃 = 0.046). Apelin,
age, and eGFR were independent predictors of mortality, and apelin, creatinine, eGFR, resistin, and visfatin were independent
predictors of hospitalization. Apelin levels were negatively correlated with cardiovascular risk factors and positively correlated with
eGFR. Patients with lower apelin levels were more likely to start a depurative technique. Conclusions. Apelin levels might have a
significant clinical use as a marker/predictor of cardiovascular mortality and hospitalization or even as a therapeutic agent for CKD
patients with cardiovascular disease.
1. Introduction
Cardiac diseases are independently associated with a deterio-
ration of renal function and worsening of existing kidney dis-
ease. On the other hand, chronic kidney disease (CKD) is
an independent risk factor for increased cardiovascular mor-
bidity and mortality [1]. It has a complex pathogeneses, and
traditional risk factors are not able to fully explain its high
incidence and prevalence [2].
Aftermany years of understanding as a simple fat storage,
adipose tissue is nowadays considered an active endocrine
organ with effects on other organs and systems [3]. Several
substances produced by adipocytes—adipokines—have been
identified, and they seem to play important roles in different
physiological functions. They act at various levels, includ-
ing the immune, endocrine, metabolic, and cardiovascular
systems [4]. Among these substances, visfatin, resistin, and
apelin might be implicated on the cardiorenal axis dysfunc-
tion [5].
Apelin, a circulating peptide produced and secreted by
adipocytes, is a ligand for the APJ receptor [6]. Both apelin
and APJ mRNA are abundantly expressed in a variety of
tissues including kidneys and at various sites within the
cardiovascular system [7]. Recent studies indicate that apelin
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signaling may be involved in the regulation of vascular tone,
cardiac contractile function, and fluid balance [8].
Nowadays there are an increasing number of studies asse-
ssing apelin in an attempt to clarify its role as a cardiovascular
disease (CVD) marker. Despite the notable interest in this
relatively new adipokine, there are still many unknowns,
and, in some cases, opposite results have been described.
Furthermore, there is a lack of studies evaluating apelin
on cardiovascular disease in patients with underlying renal
failure.
In the present studywe evaluated the association of apelin
levels with mortality and hospitalization events, as well as the
relationship of apelin with renal function and cardiovascular
risk factors, in a homogeneous population of type 2 diabetic
patients with a diagnosis of mild to moderate CKD.
2. Material and Methods
An observational, prospective study involving 150 patients
with type 2 diabetes mellitus was conducted in our outpatient
diabetic nephropathy clinic from January 2005 to December
2011.
2.1. Subjects. Type 2 diabetic patients with a diagnosis ofmild
to moderate CKD (15mL/min/1.73m2 < eGFR ≤ 80mL/
min/1.73m2)were eligible to participate in the study.The clas-
sification of diabetes was performed based on the guidelines
from the American Diabetes Association [9].
The exclusion criteria were previous CVD—defined as a
history of one or more of the following: nonfatal myocardial
infarction, angina pectoris (stable or unstable), stroke or
transient ischemic attacks, peripheral vascular disease or
congestive heart failure, uncontrolled hypertension (BP ≥
140/90mmHg), albumin/creatinine ratio (UACR) > 500,
eGFR ≤ 15mL/min or > 80mL/min, PTH ≥ 350mmHg,
phosphorus > 5.5, type 1 diabetes, nondiabetic renal disease,
or neoplastic or infectious diseases.
All mortalities and hospitalization motivated by causes
other than cardiovascular events were excluded.
Patients were recruited on an outpatient nephrology con-
sultation.
2.2. Follow-Up. Patients returned on a regular basis for in-
person visits on nephrology consultation two to three times
a year.The continuity of the follow-up of patients in the same
institution is assured since in the Algarve region patients with
renal disease are referred to Hospital de Faro.
2.3. Hospitalization. The evaluation and characterization of
hospitalization were based on the hospital admission clinical
record, which provides information regarding signs and
symptoms, diagnostic exams, procedures, treatments, and
diagnosis on the day of discharge.
2.4. Blood Measurements. Serum samples were collected at
baseline in fasting patients, and patients were divided accord-
ing to the apelin-36 groups. Samples were centrifuged, and
plasma was frozen at −80∘C. At the time of sample collec-
tion for dosing apelin, other laboratorial parameters were
Table 1: Patients’ baseline characteristics.
Characteristics Values
Number of patients enrolled, 𝑛 150
Age (years) 62.67 ± 10.95
Gender, M/F (%) 92/58 (61.3/38.7)
BMI (Kg/m2) 26.3 ± 2.7
Blood pressure (mmHg) 130.9/77.4 ± 18.1/10.9
Hb (g/dL) 12.6 ± 1.9
HgA1c (%) 7.5 ± 1.5
Total cholesterol (mg/dL) 192.7 ± 40.1
Triglycerides (mg/dL) 154.8 ± 88.9
PTH (pg/mL) 138.9 ± 50.8
Phosphorus (mg/dL) 4.3 ± 1.2
Calcium (mg/dL) 9.4 ± 0.9
Creatinine (mg/dL) 1.9 ± 1.0
Albumin/creatinine ratio (𝜇g/mg) 244.9 ± 116.0
eGFR (mL/min) 42.7 ± 23.6
Albumin (g/dL) 4.1 ± 0.6
HDL (mg/dL) 50.4 ± 20.8
LDL (mg/dL) 113.0 ± 30.7
Apelin (pg/mL) 216.2 ± 45.3
IL-6 (pg/mL) 6.2 ± 3.8
Resistin (pg/mL) 6.1 ± 3.5
Visfatin (pg/mL) 62.0 ± 59.7
Adiponectin (ng/mL) 28.6 ± 8.6
OxLDL (U/L) 45.7 ± 22.8
LVMI (g/m2) 105.2 ± 25.7
PP (mmHg) 53.1 ± 19.3
measured. The option to analyze apelin levels by groups
rather than by a continuous variable was made in order to try
to better differentiate the power of lower and higher apelin
levels.
The first group consisted of patients with apelin ≤98 pg/
mL, group 2 included patients with apelin 98–328 pg/mL,
and group 3 encompassed patients with apelin ≥329 pg/mL.
In the absence of values defined for mild and moderate
cardiovascular risk, the range for each apelin group was obta-
ined from the 25th, 50th, and 75th percentiles of our sample’s
baseline apelin values.
Several laboratory parameters were analyzed: albu-
min, hemoglobin (Hb), glycated hemoglobin (HgA1c), total
cholesterol, HDL cholesterol, LDL cholesterol, triglycerides,
mineral metabolism (Ca, P, and PTH), inflammation (Inter-
leukin-6 (IL-6)), insulin resistance (homeostasis model
assessment: estimated insulin resistance (HOMA-IR)), adip-
okines (resistin, visfatin, and adiponectin), oxidative stress
(oxidized low-density lipoprotein (oxLDL)), and albumin/
creatinine ratio (Table 1). To normalize the distribution of
plasma visfatin, log transformation was used.
The quantification of apelin was determined using an
enzyme immunoassay kit, FEIA kit (Cat. no. FEK-057-15;
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Phoenix Pharmaceuticals Inc., Burlingame, CA, USA), desig-
ned to detect a specific peptide and its related peptides based
on the principle of “competitive” enzyme immunoassay.
The immunoplate in this kit is precoated with secondary
antibody, and the nonspecific binding sites are blocked. The
secondary antibody can bind to the Fc fragment of the
primary antibody (peptide antibody) whose Fab fragment
will be competitively bound by both biotinylated peptide
and peptide standard or targeted peptide in samples. The
biotinylated peptide interacts with streptavidin-horseradish
peroxidase (SA-HRP) which catalyzes the substrate solution.
The fluorescence intensity is directly proportional to the
amount of biotinylated peptide SA-HRP complex. A standard
curve of known concentration can be established accordingly.
Theunknown concentration in samples can be determined by
extrapolation to this standard curve.
The quantification of resistin and visfatin was determined
by enzyme-linked immunosorbent assay using the ELISA
kits (Cat. no. EK-028-36; Phoenix Pharmaceuticals Inc., Bur-
lingame, CA, USA) and (Cat. no. EK-003-80; Phoenix Phar-
maceuticals Inc., Burlingame, CA, USA), respectively. Both
techniques were adapted to the Triturus automatic micro-
plate apparatus (Grifols S.A., Barcelona, Spain). Plasma adip-
onectin was measured using a human adiponectin RIA Kit
(Lincoln Research).
The serum levels of cholesterol, triglycerides, HDL, phos-
phorus, and calcium were measured using the ARCHITECT
c Systems and the AEROSET System (Abbott Diagnostics
Division, Abbott Laboratories Abbott Park, IL).
The low-density lipoprotein (LDL) cholesterol in human
plasma was assessed using aMULTIGENTDirect LDL Assay
(Abbott Diagnostics Division, Abbott laboratories Abbott
Park, IL).
Serum levels of IL-6 were measured using a sandwich
enzyme-linked immunoassay (ELISA) kit (eBioscience, San
Diego, CA, USA), andOxLDLwasmeasured using an immu-
noenzymatic assay.
Hemoglobin, glycated hemoglobin, and PTH levels were
measured using a spectrophotometry technique, a high-
performance liquid chromatography (HPLC), and electro-
chemiluminescent immunoassay (ECLIA), respectively.
2.5. Insulin ResistanceAssessment. Thedegree of insulin resis-
tance was estimated using the homeostasis model assessment
(HOMA-IR) described by Matthews et al. [10]. HOMA was
calculated using the following formula:
HOMA-IR (mmol/L × 𝜇U/mL)
= fasting glucose (mmol/L)
× fasting insulin (𝜇U/mL) /22.5.
(1)
2.6. Renal Function Assessment. This analysis included all
participants with creatinine measures at baseline. Serum
creatinine was measured by the enzymatic method, using the
ARCHITECT device (Abbott Diagnostics Division, Abbott
Laboratories Abbott Park, IL). GFR was estimated using a
formula derived by the modification of diet in renal disease
study group as follows [11]:
eGFR = 186.3 × (serum creatinine)−1.154 × age−0.203
× (0.742 if female) × (1.21 if black) .
(2)
2.7. Echocardiography. Transthoracic echocardiography was
performed using a General Electrical Medical Systems Echo-
graph, model Vivid 7 with a probe (GE Healthcare, Wiscon-
sin, USA). Data were recorded on computer and film and
were analyzed always by the same technician.
2.8. Carotid Echodoppler. Carotid echodoppler was per-
formed using a General Electrical Medical Systems Echo-
graph, model Vivid 4 with a linear probe of 10MHz (GE
Healthcare, Wisconsin, USA). For the assessment of the
carotid artery intima-media thickness (IMT), the protocol
of the American Society of Echocardiography was followed.
Data were recorded and analyzed by the same technician.
2.9. Definitions. Left ventricular mass index (LVMI) was
calculated by applying the regression equation from Penn
convention:
LV mass = 1, 04 ([LVIDD + PWTD + IVSTD]3
−[LVIDD]3) − 13, 6 g,
(3)
where LVIDD is the left ventricular internal diameter in
diastole, PWTD is the posteriorwall thickness in diastole, and
IVSRD is the interventricular septum thickness in diastole.
LVMIwas then obtained by dividing LVmass by body surface
area.
PP was considered as the difference between systolic and
diastolic pressures:
PP = systolic pressure − diastolic pressure. (4)
Increased cardiovascular risk was considered for PP
values greater than 50mmHg and IMT > 0.9.
2.10. Outcomes. The primary outcome of this study was
cardiovascular mortality. Deaths were confirmed by review
of autopsy reports, death certificates, medical records, or
information obtained from the next of kin or familymembers
and classified, according to its cause, as cardiovascular or
noncardiovascular death. Cardiovascular deathswere defined
as mortality caused by coronary heart disease, heart failure,
peripheral vascular disease, and cerebrovascular disease.
Secondary outcomes comprised hospitalization due to
cardiovascular causes and the assessment of any possible
relationship between apelin and renal disease.
Hospitalization days were also classified as due to cardio-
vascular causes or due to noncardiovascular causes. Hospi-
talization days due to cardiovascular causes which met the
same criteria for cardiovascular deaths but with no mortality.
Progression of renal failure was assessed during the follow-up
consultations by performing analytical evaluations of renal
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Table 2: Comparison of variables among the 3 apelin-36 tertiles.
Group 1
(<98 pg/mL)
𝑛 = 50
Group 2
98–328 (pg/mL)
𝑛 = 50
Group 3
≥329 (pg/mL)
𝑛 = 50
𝑃 value
Resistin (pg/mL) 1.0 ± 0.3 0.8 ± 0.6 0.5 ± 0.3 <0.001
Log visfatin (pg/mL) 2.1 ± 1.7 1.7 ± 1.7 1.3 ± 1.4 <0.001
Adiponectin (ng/mL) 10.8 ± 7.9 30.1 ± 16.5 45.7 ± 18.7 <0.001
Interleukin-6 (IL-6) (pg/mL) 8.8 ± 3.0 6.4 ± 4.0 3.3 ± 1.8 <0.001
Oxidized LDL (OxLDL) (U/L) 67.3 ± 18.7 39.0 ± 19.0 30.1 ± 9.1 <0.001
Estimated glomerular filtration rate (eGFR) (mL/min) 29.7 ± 20.3 48.6 ± 21.2 49.5 ± 24.1 <0.001
Homeostasis model of assessment: insulin resistance (HOMA-IR) 3.8 ± 1.3 2.1 ± 1.5 0.6 ± 0.4 <0.001
Parathyroid hormone (PTH) (pg/mL) 217.4 ± 135.0 120.2 ± 61.4 76.3 ± 41.2 <0.001
Phosphorus (mg/dL) 5.2 ± 1.4 4.3 ± 0.8 3.6 ± 0.7 <0.001
Albumin/creatinine ratio 268.9 ± 108.6 255.5 ± 123.8 209.2 ± 108.7 0.026
Left ventricular mass index (LVMI) (g/m2) 133.2 ± 16.2 100.5 ± 15.3 80.8 ± 9.1 <0.001
Intima-media thickness (IMT) (mm) 1.2 ± 0.2 1.0 ± 0.3 0.8 ± 0.1 <0.001
Pulse pressure (PP) (mmHg) 68.7 ± 13.9 47.0 ± 19.3 43.1 ± 12.3 <0.001
function (measurement of creatinine and estimation ofGFR).
Patients with an eGFR< 10mL/min started a depurative tech-
nique (DT), hemodialysis, or peritoneal dialysis according to
patient’s choice.
2.11. Statistical Analyses. We used descriptive statistics, and
for comparison between groups we used the ANOVA test.
TheKaplan-Meiermethod formeasuring patient survival rate
was applied, and a comparison between the three tertiles
was based on the log rank test. The risk factors and their
hazard ratio (HR) were calculated using a backward stepwise
likelihood ratio (LR) Cox regression for mortality and a
multivariate logistic regression for hospitalization. Simple
linear regressions and Pearson correlations were used to
investigate any possible correlation between apelin and renal
disease and between apelin and cardiovascular risk factors.
Differences were considered statistically significant for 𝑃
values < 0.05. Statistical analyses were performed using the
SPSS program, v17.0.
The study was submitted to and approved by the admin-
istration and ethics committee. The study was conducted
according to the principles of the Declaration of Helsinki.
Study procedures were only performed after signing the
informed consent.
3. Results
A total of 150 patients were evaluated during a 87-month
period from January 2005 to December 2011. The mean age
of these patients was 62.67 ± 10.95 years (42–87), and 38.7%
of them (58) were female. The mean follow-up time was
35.7 ± 15.3months (8–87).
In terms of allocation of patients into groups according
to their serum apelin-36 values and following the definition
of the 25th, 50th, and 75th percentiles, all three groups
encompassed a total of 50 patients. All the assessed variables
presented significant differences between the three apelin
level groups (Table 2).
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Figure 1: Kaplan-Meier survival analysis.
As presented in Table 2, patients of group 3 revealed
higher adiponectin levels and greater eGFR, as well as lower
values of resistin, log visfatin, IL-6, OxLDL, HOMA-IR,
LVMI, PP, IMT, PTH, and phosphorus.
Using the Kaplan-Meier analysis, it was observed that
patients’ survival at 83 months was 39% in group 1, 40% in
group 2, and 71.2% in group 3 (Figure 1). The log rank test
confirmed the existence of significant differences between the
three groups (log rank = 6.413; 𝑃 = 0.046).
Variables such as age, sex, apelin-36 levels, HOMA-IR,
adiponectin, IL-6, phosphorus, PTH, eGFR, creatinine, Hb,
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Table 3: Multivariate Cox regression analysis results for cardiovas-
cular mortality.
Adjusted HR (95% CI) 𝑃 value
Age 1.013 (1.103–2.107) 0.016
Sex 1.088 (0.251–4.718) 0.910
Apelin 0.981 (0.967–0.996) 0.012
HOMA-IR 0.987 (0.922–1.901) 0.968
Adiponectin 0.885 (0.786–0.996) 0.742
IL-6 1.124 (0.881–1.434) 0.349
Phosphorus 1.585 (0.969–2.594) 0.067
PTH 1.000 (0.992–1.007) 0.922
eGFR 0.886 (0.790–0.997) 0.043
Creatinine 1.152 (1.138–1.937) 0.328
Hb 1.701 (1.103–2.625) 0.216
OxLDL 1.063 (0.995–1.136) 0.071
Resistin 0.674 (1.458–6.679) 0.423
Visfatin 0.654 (1.106–3.724) 0.347
Table 4: Mortality and Cox regression results by group of apelin.
Apelin group
(pg/mL) No. of patients No. of deaths
Adjusted HR
(95% CI)
≤98 50 17 Reference
98–329 50 14 0.388 (0.078–1.345)
≥329 50 4 0.026 (0.013–0.954)
OxLDL, resistin, and visfatin were analyzed using a multi-
variate Cox regression to identify independent risk factors
of mortality. Age, eGFR, and apelin-36 levels were found to
predict patient survival (𝑃 < 0.05) in opposition to sex,
HOMA-IR, adiponectin, IL-6, phosphorus, PTH, creatinine,
Hb, OxLDL, resistin and visfatin (𝑃 > 0.05) (Table 3). A stati-
stically significant decrease in mortality was observed with
apelin levels ≥329 pg/mL (Table 4).
Regarding cardiovascular hospitalization, patients in
group 1 presented a greater mean length (15.2 ± 15.8 days (0–
79)) when compared with patients in group 2 (4.7 ± 7.4 days
(0–34)) and group 3 (0.9 ± 2.9 days (0–14)). These differences
between groups were statistically significant (𝑃 < 0.001).
In order to identify independent risk factors for hos-
pitalization, variables such as age, sex, apelin, adiponectin,
IL-6, eGFR, creatinine, LVMI, OxLDL, resistin, and visfatin
were analyzed through a multivariate logistic regression.
Creatinine, eGFR, and the adipokines apelin, resistin, and
visfatin were found to predict the need for hospitalization
(𝑃 < 0.05) in opposition to the other assessed variables
(𝑃 > 0.05) (Table 5). A statistically significant decrease in
the risk of hospitalization was observed with apelin levels
≥329 pg/mL (Table 6).
The association of apelin with renal disease and cardio-
vascular risk factors was also assessed. By applying simple
linear regressions, serum apelin levels were found to be
negatively correlated with IMVE (𝑅 = −0.588, 𝑃 = 0.0001),
creatinine (𝑅 = −0.316, 𝑃 = 0.0001), IL-6 (𝑅 = −0.708,
𝑃 = 0.0001), IMT (𝑅 = −0.621, 𝑃 = 0.0001), systolic BP
Table 5: Multivariate logistic regression analysis results for cardio-
vascular hospitalization.
Adjusted OR (95% CI) 𝑃 value
Age 0.974 (0.912–1.040) 0.434
Sex 0.852 (0.218–3.330) 0.818
Apelin 0.548 (0.302–0.817) 0.004
Adiponectin 0.941 (0.879–1.008) 0.083
IL-6 1.017 (0.800–1.294) 0.889
eGFR 0.983 (0.940–1.029) 0.464
Creatinine 1.095 (1.066–1.144) 0.037
LVMI 1.024 (0.970–1.081) 0.386
OxLDL 1.056 (0.995–1.122) 0.072
Resistin 1.097 (0.992–1.192) 0.043
Visfatin 1.035 (1.008–1.061) 0.009
Table 6: Hospitalization and logistic regression results by group of
apelin.
Apelin group
(pg/mL)
No. of
patients
No. of patients
hospitalized
Adjusted OR
(95% CI)
≤98 50 35 Reference
98–329 50 29 0.667 (0.558–1.748)
≥329 50 9 0.615 (0.439–1.319)
Table 7: Depurative technique and logistic regression results by
group of apelin.
Apelin group
(pg/mL)
No. of
patients
No. of patients
starting a DT
Adjusted OR
(95% CI)
≤98 50 20 Reference
98–329 50 10 1.500 (0.520–4.323)
≥329 50 7 0.871 (0.456–1.492)
(𝑅 = −0.441, 𝑃 = 0.0001), PP (𝑅 = −0.588, 𝑃 = 0.0001),
and OxLDL (𝑅 = −0.669, 𝑃 = 0.0001), while it was positively
correlated with eGFR (𝑅 = 0.357, 𝑃 = 0.0001). These results
were confirmed by Pearson correlations.
Finally, we also investigated the association of apelin lev-
els and the progression of renal disease. It was observed that
age and levels of apelin and phosphorus were independent
predictors of patients’ renal disease progression to a DT (𝑃 <
0.05). There was also a statistically significant decrease in the
risk of progression to a DT with apelin levels >329 pg/mL
(Table 7).
4. Conclusions
We evaluated the association of apelin levels with mortality
and hospitalization events, as well as the relationship of apelin
with renal function and cardiovascular risk factors, in a
homogeneous population of type 2 diabetic patients with a
diagnosis of mild to moderate CKD.
The mortality data collected revealed significant differ-
ences among the three apelin groups. Patients with higher
apelin levels tended to have better survival rates than patients
with lower levels of apelin. Furthermore, using Cox analysis,
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apelin was found to independently predict patient survival,
with a decreased risk of cardiovascular mortality associated
with higher apelin levels. All three groups of apelin presented
established cardiovascular risk factors, so we believe there is
an unbalance that leads to an increased production of activat-
ing factors (e.g., resistin, visfatin, PTH, and phosphorus) and
a decreased production of protective factors (e.g., apelin) that
may explain these results.
The results of our survival functions demonstrated that
lower apelin levels are predictive of cardiovascular mortality
in type 2 diabetic patients with a diagnosis of mild to mod-
erate CKD. To our knowledge, although the association of
apelin and the cardiorenal axis is not new, so far there are no
published studies that corroborate this association between
apelin and cardiovascular mortality. Thus, our results raise
interest for further analysis assessing apelin as a possible
marker/predictor of cardiovascular mortality in this popula-
tion.
Similar results were obtained when assessing cardiovas-
cular hospitalization and progression of renal disease in
this population. Multivariate logistic regression analysis pre-
sented apelin as a predictive variable of the need for cardio-
vascular hospitalization and for progression of renal disease
to a DT. Lower apelin levels were associated with increased
risks of cardiovascular hospitalization and disease progres-
sion.
We also approached the association of apelin levels with
renal disease and cardiovascular risk factors. Our results
suggested that apelin levels were inversely correlated with
well-known cardiovascular risk factors such as LVMI, IMT,
systolic BP, PP, and OxLDL and directly correlated with
the renal function parameter eGFR. Thus, it seems that, as
apelin increases, renal function improves and cardiovascular
risk decreases. This data seems to be in accordance with a
previously reported study [12] that has already correlated
apelin with some echocardiographic features and inflam-
matory markers in hemodialyzed patients. Interestingly, a
recent study by Leal et al. [13], analyzing apelin plasma levels
in hemodialyzed patients, refuted that apelin could possi-
bly be associated with cardiovascular risk in hemodialyzed
patients. Further studies with greater sample size and robust
statistical analysis are necessary in order to better inquire
the association between apelin and cardiovascular disease
pathogenesis and risk. It would be particularly interesting to
conduct further studies in earlier stages of renal disease since
we present, in opposition to the other mentioned studies,
results of patients that were not undergoing any DT at the
beginning of the study.
In conclusion, our results suggest that, among the ana-
lyzed variables, apelin, age, and eGFR are themain predictors
of cardiovascular mortality, and apelin, creatinine, resistin,
and visfatin are the main predictors of hospitalization in type
2CKDdiabetic patients.Our results also tend to show that the
lower the level of apelin, the greater the risk of cardiovascular
mortality and hospitalization. In addition, it was observed
that apelin seems to be associated with the progression of
renal disease to a DT, with patients in the group of lower
apelin levels beingmore likely to start a depurative technique.
This might be possibly associated with a potential protective
role of apelin; however, further studies are necessary in order
to clearly define this association. Finally, we have also found
that apelin levels are negatively correlated with well-known
cardiovascular risk factors and positively correlated with
eGFR. This fact enhances the possibility of a cardiovascular
and renal protective role of apelin. These results demonstrate
that apelin levels might have a significant clinical use as a
marker/predictor of cardiovascular mortality and need for
hospitalization, and a therapeutic role for CKD patients with
cardiovascular disease is plausible.
Despite the relatively small sample studies and the limited
statistical power of these analyses, features that can be pointed
as the main limitations of this paper, these are preliminary
results of a long-term project, and future stronger data will
be presented. However, these initial results already present
new important insights regarding the association of apelin
and cardiovascularmortality, as we believe that this is the first
paper presenting apelin as a predictor of mortality in diabetic
patients with mild to moderate CKD.
We believe further studies are required in order to con-
firm these associations, particularly to assess a possible cardi-
oprotector role of apelin, in earlier stages of renal disease, as
well as to clarify how it interacts with other nontraditional
cardiovascular risk factors on renal disease.
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